Health Technology · Pharmaceuticals: Major · NSE: WANBURY · data 2026-10-09

Wanbury Limited

Health check: Average (5.3/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹196.42

Market cap

₹679 cr

P/E

12.1

P/B

—

ROE

64.9%

ROCE

31.1%

Debt / equity

1.57

Dividend yield

0.00%

1-year return

-21.6%

52-week high

₹358.85

52-week low

₹161.5

Operating margin

12.8%

Growth

Revenue (last 12 months)	₹653 cr
Net profit (last 12 months)	₹56 cr
Sales growth, 3 years (yearly)	8.9%
Profit growth, 3 years (yearly)	—

Chart patterns

Double top — breakdown (key level ₹230)
Death cross — breakdown (key level ₹253.23)

Similar companies

Hexagon Nutrition Limited (HEXAGON) · Anuh Pharma Limited (ANUHPHR) · Amanta Healthcare Limited (AMANTA) · Valiant Laboratories Ltd. (VALIANTLAB) · Praveg Limited (PRAVEG)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open WANBURY in NSE Scanner →